NSE · Healthcare · Diagnostics & Research
EPS came in at 3.42 against a street estimate of 3.60 — a miss of 5.0%.
with an average price target of ₹1,552.67.
CONFIDENT Sai Life Sciences grew 12% YoY in Q1 FY27, driven by 26% CRO growth. Management emphasizes deepening pharma relationships, FTE contracts, and multi-modality expansion (peptides, conjugates, formulation). Guidance 15–20% midterm growth maintained. Q1 FY27 No regional breakdown provided by management. Analysts pressed on Big Pharma acceleration (confirmed), formulation economics (clinical-only, non-core), and FTE retention odds (high, due to relationship depth). Management fielded defensively on 15–20% guidance, citing lumpiness and 3–5 year view, despite 30% prior-year growth. 2026-08-07…
Full summary in the app.
| Holder | Stake |
|---|---|
| Invesco India Flexi Cap Fund | 7.43% |
| Nippon Life India Trustee Ltd-a/c Nippon India Mul | 6.79% |
| Axis Mutual Fund Trustee Limited A/C Axis Mutual F | 3.19% |
| Aditya Birla Sun Life Mutual Fund - Aditya Birla S | 2.81% |
| Smallcap World Fund, Inc | 2.57% |
| Document | Date |
|---|---|
| Annual report FY2026 SAI LIFE SCIENCES LIMITED – FY 2025-26 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Revenue: ₹2,192 Cr., up 29% year-on-year • Profit After Tax ( | 2026-08-25 |
| Q1 FY27 earnings call SAI LIFE SCIENCES LIMITED - Q1 FY27 EARNINGS SUMMARY HEADLINE NUMBERS • Total revenue Q1 FY27: INR 553 crores (12% YoY growth vs INR 496 crores in Q | 2026-08-12 |
| Investor presentation · Q1 FY27 SAI LIFE SCIENCES LIMITED – INVESTOR SUMMARY Q1 FY27 (Quarter Ended 30 June 2026) --- HEADLINE NUMBERS • Revenue: ₹554 crore – up 12% year-on-year | 2026-08-07 |
| Quarterly results · Q1 FY27 SAI LIFE SCIENCES LIMITED – Q1 FY27 SUMMARY HEADLINE NUMBERS • Revenue from Operations: ₹554 crore in Q1FY27 vs ₹496 crore in Q1FY26 — 12% YoY growt | 2026-08-06 |
| Q4 FY26 earnings call DOCUMENT SUMMARY: SAI LIFE SCIENCES LIMITED IMPORTANT NOTE This document is a cover letter only and does not contain financial results, operational d | 2026-05-21 |
| Investor presentation · Q4 FY26 SAI LIFE SCIENCES LIMITED – INVESTOR SUMMARY HEADLINE NUMBERS • Revenue FY26: ₹2,192 Cr, up 29% YoY from ₹1,695 Cr in FY25 • EBITDA FY26: ₹661 Cr, u | 2026-05-15 |
| Quarterly results · Q4 FY26 SAI LIFE SCIENCES LIMITED – FY26 FINANCIAL SUMMARY HEADLINE NUMBERS • Revenue from Operations: ₹2,192 crores in FY26 vs ₹1,695 crores in FY25 — 29% | 2026-05-14 |
| Q3 FY26 earnings call | 2026-02-13 |
Readable in the app.
| Announcement | Date |
|---|---|
| New Process R&D facility in Hyderabad to double capacity Sai Life Sciences announced plans to double its Process R&D (Research & Development) capacity by building a new facility in Hyderabad. Process R&D involves developing and optimizing manufact | 2025-10-27 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for SAI LIFE SCIENCES LTD — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.